148 related articles for article (PubMed ID: 25549142)
1. Utility of immunohistochemistry in the pancreatobiliary tract.
Lin F; Chen ZE; Wang HL
Arch Pathol Lab Med; 2015 Jan; 139(1):24-38. PubMed ID: 25549142
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin.
Lin F; Liu H
Arch Pathol Lab Med; 2014 Dec; 138(12):1583-610. PubMed ID: 25427040
[TBL] [Abstract][Full Text] [Related]
3. Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update.
Zhang K; Deng H; Cagle PT
Arch Pathol Lab Med; 2014 Dec; 138(12):1611-28. PubMed ID: 25427041
[TBL] [Abstract][Full Text] [Related]
4. The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders.
Kaspar HG; Crum CP
Arch Pathol Lab Med; 2015 Jan; 139(1):39-54. PubMed ID: 25549143
[TBL] [Abstract][Full Text] [Related]
5. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification.
Fernández Moro C; Fernandez-Woodbridge A; Alistair D'souza M; Zhang Q; Bozoky B; Kandaswamy SV; Catalano P; Heuchel R; Shtembari S; Del Chiaro M; Danielsson O; Björnstedt M; Löhr JM; Isaksson B; Verbeke C; Bozóky B
PLoS One; 2016; 11(11):e0166067. PubMed ID: 27829047
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts.
Ney JT; Zhou H; Sipos B; Büttner R; Chen X; Klöppel G; Gütgemann I
Hum Pathol; 2007 Feb; 38(2):359-64. PubMed ID: 17137615
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic challenge: intraductal neoplasms of the pancreatobiliary system.
Tajiri T; Tate G; Matsumoto K; Hoshino H; Iwamura T; Kodaira Y; Takahashi K; Ohike N; Kunimura T; Mitsuya T; Morohoshi T
Pathol Res Pract; 2012 Nov; 208(11):691-6. PubMed ID: 23057996
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.
Winter JM; Yeo CJ; Brody JR
J Surg Oncol; 2013 Jan; 107(1):15-22. PubMed ID: 22729569
[TBL] [Abstract][Full Text] [Related]
10. Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update.
Deng H
Arch Pathol Lab Med; 2024 Mar; 148(3):267-283. PubMed ID: 37406295
[TBL] [Abstract][Full Text] [Related]
11. Cystic papillary pattern in pancreatic ductal adenocarcinoma: a heretofore undescribed morphologic pattern that mimics intraductal papillary mucinous carcinoma.
Kelly PJ; Shinagare S; Sainani N; Hong X; Ferrone C; Yilmaz O; Fernández-del Castillo C; Lauwers GY; Deshpande V
Am J Surg Pathol; 2012 May; 36(5):696-701. PubMed ID: 22367300
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-1: a marker for pancreatic cancer diagnosis.
Tanase CP
Expert Rev Mol Diagn; 2008 Jul; 8(4):395-404. PubMed ID: 18598222
[TBL] [Abstract][Full Text] [Related]
13. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma.
Szafranska-Schwarzbach AE; Adai AT; Lee LS; Conwell DL; Andruss BF
Expert Rev Mol Diagn; 2011 Apr; 11(3):249-57. PubMed ID: 21463235
[TBL] [Abstract][Full Text] [Related]
14. Application of immunohistochemistry in gastrointestinal and liver neoplasms: new markers and evolving practice.
Chen ZE; Lin F
Arch Pathol Lab Med; 2015 Jan; 139(1):14-23. PubMed ID: 25549141
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts.
Yip-Schneider MT; Wu H; Dumas RP; Hancock BA; Agaram N; Radovich M; Schmidt CM
J Am Coll Surg; 2014 Apr; 218(4):608-17. PubMed ID: 24491241
[TBL] [Abstract][Full Text] [Related]
17. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
18. Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system.
Lu SH; Yuan RH; Chen YL; Hsu HC; Jeng YM
Histopathology; 2013 Nov; 63(5):640-8. PubMed ID: 24024557
[TBL] [Abstract][Full Text] [Related]
19. aPKCλ/ι is a beneficial prognostic marker for pancreatic neoplasms.
Kato S; Akimoto K; Nagashima Y; Ishiguro H; Kubota K; Kobayashi N; Hosono K; Watanabe S; Sekino Y; Sato T; Sasaki K; Nakaigawa N; Kubota Y; Inayama Y; Endo I; Ohno S; Maeda S; Nakajima A
Pancreatology; 2013; 13(4):360-8. PubMed ID: 23890134
[TBL] [Abstract][Full Text] [Related]
20. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
